Plant Name: Schisandra chinensis
Taxonomic Information:
Plant ID: NPO8187
Plant Latin Name: Schisandra chinensis
Taxonomy Genus: Schisandra
Taxonomy Family: Schisandraceae
Plant External Links:
NCBI TaxonomyDB:
50507
Plant-of-the-World-Online:
60456331-2
Used in Medicines:
Country/Region:
South Korea; China; Russia; South AfricaTraditional Medicine System:
TCM; KampoMedicinal Functions:
Antirheumatic; Antitussive; Aphrodisiac; Astringent; Cancer; Cardiotonic; Cholagogue; Expectorant; Hepatic; Lenitive; Nervine; Pectoral; Sedative; Stimulant; Tonic
Geographical Distribution:
Japan; South Korea; China; Russia; South Africa
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| LTB4R; ADRA2B; | |
| NPSR1; | |
| RECQL; FAAH; TDP1; HSD11B1; ALOX12; HSD17B10; ALOX15; NOX4; POLB; | |
| ACHE; | |
| TRPV1; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA14; CA7; CA4; | |
| RXRA; | |
| ESR1; | |
| NR3C1; | |
| ALOX5; | |
| HIF1A; | |
| LMNA; RAB9A; NPC1; MAPT; PAX8; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Small molecule receptor (family A GPCR) | LTB4R | Leukotriene B4 receptor 1 | Q15722 | CHEMBL3911 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.270E-10 | 2.765E-06 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.378E-08 | 9.534E-05 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.315E-07 | 7.240E-04 | HIF1A, KDR, MAPT, NR3C1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.190E-06 | 9.258E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.391E-06 | 9.993E-04 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.968E-06 | 1.539E-03 | CYP19A1, CYP1B1, CYP3A4, NOX4 |
| MF | Unclassified; | GO:0004872; receptor activity | 3.817E-06 | 1.696E-03 | ADRA2B, AXL, ESR1, FLT3, IGF1R, KDR, LTB4R, MET, NPC1, NPSR1, NR3C1, PAX8, RXRA, TRPV1 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.841E-06 | 1.982E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.841E-06 | 1.982E-03 | ALOX12, ALOX15 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 5.031E-06 | 1.992E-03 | ALOX12, CA12, CA2, CA7, ESR1, HIF1A, MET, NOX4, NPC1, NPSR1, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.639E-06 | 2.154E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0008152; metabolic process | GO:0019369; arachidonic acid metabolic process | 6.208E-06 | 2.331E-03 | ALOX12, ALOX15, CYP1B1, FAAH |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 7.008E-06 | 2.586E-03 | ALOX15, AXL, CA2, CDK1, CYP1B1, HIF1A, KDR, NPC1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.131E-05 | 3.973E-03 | CYP1B1, ESR1, FLT3, NOX4, NPC1, NR3C1, TRPV1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.450E-05 | 4.576E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.450E-05 | 4.576E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.450E-05 | 4.576E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 1.760E-05 | 5.310E-03 | ALOX15, AXL, CA2, CDK1, CYP1B1, HIF1A, LMNA, MAPT, NOX4, POLB, RECQL, TDP1, TRPV1 |
| BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 1.818E-05 | 5.310E-03 | ACHE, HSD17B10, IGF1R, RXRA, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.764E-05 | 5.310E-03 | CYP19A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 3.238E-05 | 8.013E-03 | CYP19A1, CYP3A4, ESR1 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 3.554E-05 | 8.324E-03 | CYP1B1, HIF1A, MAPT, NOX4, TRPV1 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.959E-05 | 8.796E-03 | CYP3A4, ESR1, NPC1, NR3C1 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.422E-05 | 9.441E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0002376; immune system process | GO:0030097; hemopoiesis | 4.530E-05 | 9.576E-03 | FLT3, HIF1A, KDR, L3MBTL1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 4.820E-05 | 9.902E-03 | ALOX12, ALOX15 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.193E-10 | 1.995E-08 | CA12, CA2, CA4, CA7, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.969E-06 | 1.806E-04 | ALOX5, CYP1B1, CYP19A1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.221E-06 | 2.190E-04 | HSD11B1, CYP1B1, CYP3A4, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 7.214E-05 | 1.313E-03 | KDR, HIF1A, ESR1, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.075E-05 | 9.270E-04 | RXRA, PAX8, FLT3, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.930E-04 | 2.926E-03 | RXRA, PAX8, FLT3, HIF1A, MET, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.205E-04 | 4.166E-03 | ALOX5, ALOX15, ALOX12 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.029E-04 | 4.583E-03 | FLT3, MET, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.184E-04 | 4.718E-03 | HSD11B1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.778E-04 | 4.718E-03 | RXRA, CA2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.283E-04 | 6.025E-03 | HSD11B1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.110E-03 | 8.418E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; ALOX5; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | LTB4R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | NR3C1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; FLT3; ACHE; HIF1A; NR3C1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; NR3C1; LTB4R; ALOX5; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | LTB4R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1; ALOX5; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| NA: NA | Edema | NA | CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; TRPV1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; FAAH; CDK1; IGF1R; ACHE; TRPV1; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; NR3C1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; LTB4R; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; LTB4R; ALOX5; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; ALOX5; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; TRPV1; ALOX5; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; LTB4R; TRPV1; ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH; ACHE; NR3C1; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; LTB4R; ALOX5; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; MAPT; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | LTB4R; ALOX5; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NR3C1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; LTB4R; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; LTB4R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; LTB4R; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
